Oragenics Inc (OGEN) - Total Liabilities
Based on the latest financial reports, Oragenics Inc (OGEN) has total liabilities worth $1.31 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OGEN financial resilience to evaluate the company's liquid asset resilience ratio.
Oragenics Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how Oragenics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Oragenics Inc total assets.
Oragenics Inc Competitors by Total Liabilities
The table below lists competitors of Oragenics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blue Star Capital plc
LSE:BLU
|
UK | £19.51K |
|
Rocky Mountain Liquor Inc
V:RUM
|
Canada | CA$12.40 Million |
|
SRT Marine Systems plc
LSE:SRT
|
UK | GBX60.55 Million |
|
Performance One AG
F:PO1
|
Germany | €4.19 Million |
|
Newpeak Metals Ltd
AU:NPM
|
Australia | AU$368.94K |
|
Neurizer Ltd
AU:NRZ
|
Australia | AU$60.54 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Oragenics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Oragenics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 133.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oragenics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oragenics Inc (2003–2025)
The table below shows the annual total liabilities of Oragenics Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.79 Million | +6.05% |
| 2024-12-31 | $1.68 Million | -6.33% |
| 2023-12-31 | $1.80 Million | +2.83% |
| 2022-12-31 | $1.75 Million | +0.23% |
| 2021-12-31 | $1.74 Million | -4.97% |
| 2020-12-31 | $1.84 Million | -27.18% |
| 2019-12-31 | $2.52 Million | +115.92% |
| 2018-12-31 | $1.17 Million | +29.94% |
| 2017-12-31 | $898.52K | -33.12% |
| 2016-12-31 | $1.34 Million | +28.27% |
| 2015-12-31 | $1.05 Million | +31.53% |
| 2014-12-31 | $796.27K | -19.80% |
| 2013-12-31 | $992.85K | -20.98% |
| 2012-12-31 | $1.26 Million | -86.70% |
| 2011-12-31 | $9.45 Million | +160.44% |
| 2010-12-31 | $3.63 Million | +543.98% |
| 2009-12-31 | $563.21K | -68.20% |
| 2008-12-31 | $1.77 Million | +434.36% |
| 2007-12-31 | $331.49K | +1.20% |
| 2006-12-31 | $327.57K | -12.61% |
| 2005-12-31 | $374.83K | -12.75% |
| 2004-12-31 | $429.63K | +103.74% |
| 2003-12-31 | $210.87K | -- |
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation w… Read more